Androgen deprivation therapy may affect cognitive function

Trump, Donald
September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p25
The article discusses research being done on the psychological effect of androgen deprivation therapy. It references a study which appeared in the 2008 issue of "Cancer." The researchers conducted a literature research to determine the effects hormone therapy has on cognitive function in prostate cancer patients. They reported that testosterone and its by-products may affect cognition by modulating neurotransmitters and stimulating the connection between neurons.


Related Articles

  • PCa patients benefit from intermittent androgen suppression. Perry, Wes // Urology Times;May98, Vol. 26 Issue 5, p22 

    Discusses benefits of prostate cancer patients receiving intermittent androgen suppression treatment. Details on the treatment; Development of androgen-dependent progression; Other advantages of the treatment.

  • Intermittent Androgen Suppression Controls PCa. Troxel, Scott // Urology Times;Feb2000, Vol. 28 Issue 2, p13 

    Reports on the efficacy of intermittent androgen suppression in the control of prostate cancer in patients. Presentation of findings by research team led by professor S. Larry Goldenberg; Treatment cycle of patients.

  • Radiotherapy plus hormone therapy halved prostate cancer mortality.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p24 

    The article discusses research being done on the addition of radiation therapy to anti-androgen therapy for patients with prostate cancer, which references a study by Sophie Dorothea Fosså et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.

  • Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. Sho Uehara; Takeshi Yuasa; Yasuhisa Fujii; Akihiro Yano; Shinya Yamamoto; Hitoshi Masuda; Iwao Fukui; Junji Yonese // BMC Research Notes;Aug2015, Vol. 8 Issue 1, p1 

    Background: 'Flare phenomenon' after initial luteinizing hormone-releasing hormone agonist administration is a widely approved concept in the treatment of prostate cancer. In most guidelines, concomitant therapy with antiandrogens is recommended to prevent this flare phenomenon. However, there...

  • Researchers must take harder look at advanced PCa. Sieve, Vonne // Urology Times;May98, Vol. 26 Issue 5, p37 

    Focuses on advanced prostate cancer and the challenges in treating the disease. Information on androgen deprivation therapy; Details on clinical trials on three antiandrogen; Results of the clinical trials.

  • Bicalutamide. Kaisary, Amir V. // Drugs;2002, Vol. 62 Issue 17, p2481 

    Presents a guest commentary by Amir V. Kaisary concerning bicalutamide, which, since its addition to the antiandrogen family of drugs, has shown various characteristics that have established its value in the management of prostate cancer. Its role in early stages of the disease; Approaches...

  • Bicalutamide. Tyrrell, Chris J. // Drugs;2002, Vol. 62 Issue 17, p2482 

    Presents a guest commentary by Chris J. Tyrrell concerning prostate cancer as a good candidate for systemic prophylaxis following primary radical treatment. Traditional hormone therapy, including castration; The Early Prostate Cancer (EPC) program; Results of the antiandrogen bicalutamide for...

  • Bicalutamide In Early-Stage Prostate Cancer. Carswell, Christopher I.; Figgitt, David P. // Drugs;2002, Vol. 62 Issue 17, p2473 

    Bicalutamide is an oral, once-daily nonsteroidal antiandrogen. Its efficacy in localised or locally advanced prostate cancer is currently being investigated as part of the Early Prostate Cancer (EPC) programme. In the EPC programme, bicalutamide 150 mg/day, as an adjunct to radiotherapy, radical...

  • Novel Drug Shows Promise for CRPC. Schieszer, John // Renal & Urology News;Sep2009, Vol. 8 Issue 9, p20 

    The article presents a study on the treatment of men with castration-resistant prostate cancer (CRPC) in Orlando, Florida. It notes that the study found out that a novel antiandrogen with unique properties has the potential to benefit men with castration-resistant prostate cancer (CRPC). It adds...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics